Hinapril (Chinaprilum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

ACE Inhibitors

Included in the formulation
  • Accupro®
    pills inwards 
    Pfizer Manufakchuring Deutschland GmbH     Germany
  • Hinapril-C3®
    pills inwards 
    NORTH STAR, CJSC     Russia
    • АТХ:

    C.09.A.A.06   Hinapril

    Pharmacodynamics:

    The carboxyl group of quinapril interacts with the zinc atom in the angiotensin converting enzyme, thereby blocking the conversion of angiotensin I in angiotensin II, the release of norepinephrine from the endings of sympathetic fibers, the vasoconstrictor effect, the secretion of aldosterone by the adrenal cortex, and increases the bradykinin content by reducing its inactivation by the angiotensin-converting enzyme.

    Bradykinin stimulates B2-cinin receptors of the vascular endothelium, which leads to the rapid release of prostacyclin and other vasodilating substances that cause relaxation of smooth muscles.

    Inhibits the tissue renin-angiotensin system of the heart, preventing the development of myocardiofibrosis, myocardial hypertrophy and dilatation of the left ventricle. Has a cardioprotective effect, decreasing the frequency ventricular arrhythmias due to potassium-sparing action. Increases the sensitivity of tissues to insulin and excretion of uric acid by the kidneys.Slows the aggregation of platelets, does not affect the number of lipoproteins and lipids in the blood plasma.

    Pharmacokinetics:

    After oral administration, fasted to 60% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 1-2 hours. The connection with plasma proteins is 97%.

    The therapeutic effect develops 1 hour after admission. Metabolism in the liver with the formation of three metabolites, one of which (quinaprilat) shows pharmacological activity.

    The half-life of hinapril is 1-2 hours, and quinaprilat is 3 hours. Elimination with feces and kidneys.

    Indications:

    It is used for the treatment of arterial hypertension. Used in combination therapy for chronic heart failure.

    ICD-10

    IX.I10-I15.I15   Secondary Hypertension

    IX.I10-I15.I10   Essential [primary] hypertension

    IX.I30-I52.I50.9   Heart failure, unspecified

    Contraindications:

    Individual intolerance, children under 18 years.

    Carefully:

    Autoimmune diseases, disorders of coronary or cerebral circulation, stenosis of the artery of a single kidney, obliterating atherosclerosis of the lower extremities, gout, hyponatremia, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, regardless of food intake, 10 mg once a day. With insufficient effectiveness, the dose is doubled, with an interval of 4 weeks.

    The highest daily dose: 80 mg.

    The highest single dose: 40 mg.

    Side effects:

    Central and peripheral nervous system: dizziness, headache, asthenia, fatigue, confusion.

    Respiratory system: dry cough, bronchitis, bronchospasm, dyspnea.

    The cardiovascular system: heart rhythm disturbances, tachycardia, rarely - stroke.

    Digestive system: dry mouth, anorexia, nausea, vomiting, diarrhea or constipation, fulminant liver necrosis, cholestatic jaundice, pancreatitis.

    Dermatological reactions: photosensitization, alopecia.

    Sense organs: rhinitis, visual impairment.

    Urinary system: impaired renal function.

    Reproductive system: impotence.

    Allergic reactions.

    Overdose:

    Orthostatic collapse.

    Treatment is symptomatic. Hemodialysis and peritoneal dialysis is ineffective.

    Interaction:

    Reduces the absorption of tetracycline antibiotics.

    It intensifies the toxic effects of lithium preparations, increasing its concentration in the blood plasma.

    Reduce the antihypertensive effect of nonsteroidal anti-inflammatory drugs.

    Strengthen the hypotensive effect of neuroleptics, diuretics, narcotic anesthetics, antihypertensive drugs of other groups.

    With simultaneous use with potassium-sparing drugs or potassium salts, the risk of hyperkalemia increases.

    Special instructions:

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up